Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Robohogs who wrote (10037)	4/24/2007 7:08:06 AM
From: Iamarangerboy	Read Replies (1) \| Respond to of 10280

Not great Sepracor Announces First Quarter 2007 Results Tuesday April 24, 7:00 am ET MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR - News) today announced its consolidated financial results for the first quarter of 2007. For the three months ended March 31, 2007, Sepracor's consolidated revenues were approximately $331.4 million, of which revenues from Sepracor's pharmaceutical product sales were approximately $321.3 million (XOPENEX® brand levalbuterol HCl Inhalation Solution revenues were $152.5 million, XOPENEX HFA® brand levalbuterol tartrate Inhalation Aerosol revenues were $20.5 million and LUNESTA® brand eszopiclone revenues were $148.3 million). Net income for the first quarter of 2007 was approximately $22.5 million, or $0.19 per diluted share. Included in the first quarter 2007 results is an after-tax charge of $32.9 million, or $0.28 per diluted share, related to the preliminary settlement of two class action lawsuits described below. These consolidated results compare with consolidated revenues for the first quarter of 2006 of approximately $285.7 million, of which revenues from Sepracor's pharmaceutical product sales were approximately $277.5 million (XOPENEX Inhalation Solution revenues were $134.1 million, XOPENEX HFA revenues were $5.3 million and LUNESTA revenues were $138.1 million). Net income for the first quarter of 2006 was approximately $10.0 million, or $0.09 per diluted share. Sepracor repaid all of its outstanding 5% convertible subordinated debentures (approximately $451.0 million, including $11.0 million in interest) when they came due on February 15, 2007. As of March 31, 2007, Sepracor had approximately $830.3 million in cash and short- and long-term biz.yahoo.com

To: Robohogs who wrote (10037)	4/24/2007 7:25:58 AM
From: Robohogs	Respond to of 10280

UBS AGE Leer Bern CSFB Citi Me Actual Lunesta 153 157 157 145 149 148 154 148 Xop UDV 168 162 169 160 154 153 155 153 Xop MDI 17 25 22 16 23 25 32 21 Brovana 0 0 0 0 0 0 5 0 Royalties 10 9 10 10 10 9 10 10 Total 348 353 358 331 336 334 356 332 COGS 32 35 29 29 30 32 32 R+D 50 59 54 58 50 50 50 41 Sales 209 216 229 216 210 183 200 192 G+A 21 * * * 21 20 20 19 EBIT 36 40 28 26 51 54 48 Interest 11 12 8 7 4 8 10 Pretax 47 52 36 33 55 62 58 Taxes 1 3 2 2 3 3 1 Net 46 49 34 31 52 59 57 Shares 116 116 121 117 121 120 117 EPS .39 .41 .43 .40* .27 .43 .49 .48 Cash EPS .50